Self-assemble gene delivery system for molecular targeting using nucleic acid aptamer

Gene

Volumn 491, Issue 2, 2012, Pages 205-209

  Kurosaki, Tomoaki ^a,b   Higuchi, Norihide ^a   Kawakami, Shigeru ^c   Higuchi, Yuriko ^c   Nakamura, Tadahiro ^a   Kitahara, Takashi ^a   Hashida, Mitsuru ^c,d   Sasaki, Hitoshi ^a,d  

^a NAGASAKI UNIVERSITY HOSPITAL   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d KYOTO UNIVERSITY   (Japan)

Author keywords

Aptamer; Gene delivery; MUC1; PDNA; Polyethylenimine

Indexed keywords

APTAMER; DNA; MUCIN 1; NANOPARTICLE; NUCLEIC ACID; POLYETHYLENEIMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; COMPLEX FORMATION; CONTROLLED STUDY; ELECTRIC ACTIVITY; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LUNG CANCER; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PARTICLE SIZE; PRIORITY JOURNAL; ZETA POTENTIAL;

ANIMALS; APTAMERS, NUCLEOTIDE; CELL LINE, TUMOR; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; MICE; NANOPARTICLES; POLYETHYLENEIMINE; TRANSFECTION;

MUS;

EID: 81455158693     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2011.09.021     Document Type: Article

References (26)

1. Alexander J.H., Hafley G., Harrington R.A., Peterson E.D., Ferguson T.B., Lorenz T.J., Goyal A., Gibson M., Mack M.J., Gennevois D., Califf R.M., Kouchoukos N.T., PREVENT IV Investigators Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. Jama 2005, 294:2446-2454.
2. Apte R.S., Modi M., Masonson H., Patel M., Whitfield L., Adamis A.P. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. Ophthalmology 2007, 114:1702-1712.
3. Boussif O., Lezoualc'h F., Zanta M.A., Mergny M.D., Scherman D., Demeneix B., Behr J.P. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:7297-7301.
4. Chan M.Y., Cohen M.G., Dyke C.K., Myles S.K., Aberle L.G., Lin M., Walder J., Steinhubl S.R., Gilchrist I.C., Kleiman N.S., Vorchheimer D.A., Chronos N., Melloni C., Alexander J.H., Harrington R.A., Tonkens R.M., Becker R.C., Rusconi C.P. Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. Circulation 2008, 117:2865-2874.
5. Chiu S.J., Ueno N.T., Lee R.J. Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin) conjugated polyethylenimine. J. Control. Release 2004, 97:357-369.
6. Demeneix B., Behr J.P. Polyethylenimine (PEI). Adv. Genet. 2005, 53:215-230.
7. Eyetech Study Group Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology 2003, 110:979-986.
8. Ferreira C.S., Cheung M.C., Missailidis S., Bisland S., Gariépy J. Phototoxic aptamers selectively enter and kill epithelial cancer cells. Nucleic Acids Res. 2009, 37:866-876.
9. Germershaus O., Merdan T., Bakowsky U., Behe M., Kissel T. Trastuzumab-polyethylenimine-polyethylene glycol conjugates for targeting Her2-expressing tumors. Bioconjug. Chem. 2006, 17:1190-1199.
10. Gendler S.J. MUC1, the renaissance molecule. J. Mammary Gland Biol. Neoplasia 2001, 6:339-353.
11. Gilbert J.C., DeFeo-Fraulini T., Hutabarat R.M., Horvath C.J., Merlino P.G., Marsh H.N., Healy J.M., Boufakhreddine S., Holohan T.V., Schaub R.G. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 2007, 116:2678-2686.
12. Godbey W.T., Wu K.K., Mikos A.G. Tracking the intracellular path of poly(ethylenimine)/DNA complexes for gene delivery. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:5177-5181.
13. Guo P., Coban O., Snead N.M., Trebley J., Hoeprich S., Guo S., Shu Y. Engineering RNA for targeted siRNA delivery and medical application. Adv. Drug Deliv. Rev. 2010, 62:650-666.
14. Itaka K., Harada A., Yamasaki Y., Nakamura K., Kawaguchi H., Kataoka K. In situ single cell observation by fluorescence resonance energy transfer reveals fast intra-cytoplasmic delivery and easy release of plasmid DNA complexed with linear polyethylenimine. J. Gene Med. 2004, 6:76-84.
15. Kichler A., Leborgne C., Coeytaux E., Danos O. Polyethylenimine-mediated gene delivery: a mechanistic study. J. Gene Med. 2001, 3:135-144.
16. Kim K.C., Lillehoj E.P. MUC1 mucin: a peacemaker in the lung. Am. J. Respir. Cell Mol. Biol. 2008, 39:644-647.
17. Kircheis R., Wightman L., Schreiber A., Robitza B., Rössler V., Kursa M., Wagner E. Polyethylenimine/DNA complexes shielded by transferrin target gene expression to tumors after systemic application. Gene Ther. 2001, 8:28-40.
18. Kurosaki T., Kitahara T., Fumoto S., Nishida K., Nakamura J., Niidome T., Kodama Y., Nakagawa H., To H., Sasaki H. Ternary complexes of pDNA, polyethylenimine, and gamma-polyglutamic acid for gene delivery systems. Biomaterials 2009, 30:2846-2853.
19. Lemkine G.F., Demeneix B.A. Polyethylenimines for in vivo gene delivery. Curr. Opin. Mol. Ther. 2001, 3:178-182.
20. Liu B. Exploring cell type-specific internalizing antibodies for targeted delivery of siRNA. Brief. Funct. Genomic. Proteomic. 2007, 6:112-119.
21. Moase E.H., Qi W., Ishida T., Gabos Z., Longenecker B.M., Zimmermann G.L., Ding L., Krantz M., Allen T.M. Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer. Biochim. Biophys. Acta 2011, 1510:43-55.
22. Nakase M., Inui M., Okumura K., Kamei T., Nakamura S., Tagawa T. p53 gene therapy of human osteosarcoma using a transferrin-modified cationic liposome. Mol. Cancer Ther. 2005, 4:625-631.
23. Neves S.S., Sarmento-Ribeiro A.B., Simes S.P., Pedroso de Lima M.C. Transfection of oral cancer cells mediated by transferrin-associated lipoplexes: mechanisms of cell death induced by herpes simplex virus thymidine kinase/ganciclovir therapy. Biochim. Biophys. Acta 2006, 1758:1703-1712.
24. Rahn J.J., Dabbagh L., Pasdar M., Hugh J.C. The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature. Cancer 2001, 91:1973-1982.
25. Savla R., Taratula O., Garbuzenko O., Minko T. Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer. J. Control. Release 2011, 153:16-22.
26. Singh R., Bandyopadhyay D. MUC1: a target molecule for cancer therapy. Cancer Biol. Ther. 2007, 6:481-486.